Evaluation and management of polypoidal choroidal vasculopathy: Case reports and review

Clinical and Refractive Optometry

Volumn 23, Issue 5, 2012, Pages 160-170

  Besada, Eulogio ^a   Shechtman, Diana ^a   Frauens, Barry J ^a   Reynolds, Sherrol ^a   Derewyanko, Catherine ^a   Vollmer, Lori ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873554908     PISSN: 17054850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Imamura Y, Engelbert M, Iida T, Freund KB, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010;55(6):501-515.
2. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10(1):1-8.
3. Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, et al. Polypoidal choroidal vasculopathy and neovascularized agerelated macular degeneration. Arch Ophthalmol 1999;117(11):1503-1510.
4. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115(4):478-85.
5. Leal S, Silva R, Figueira J, Cachulo ML, et al. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopauiy: results after 3 years of follow-up. Retina 2010;30(8):1197-1205.
6. Koreen L, Hollar MW, Cousins SW. Where do PCV and RAP fit in the spectrum of AMD CNV subtypes? Determining lesion morphology provides for better diagnosis and treatment. Retinal Physician (www.retinalphysician. com) 2010; October issue: 1-10.
7. Lim TH, Laude A, Tan CS. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye 2010;24(3):483-490.
8. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30(9):1333-1349.
9. Lima LH, Schubert C, Ferrara DC, Merriam JE, et al. Three major loci involved in age-related macular degeneration are also associated with polypoidal choroidal vasculopathy. Ophthalmology 2010;117(8):1567-1570.
10. Kondo N, Honda S, Ishibashi K, Tsukahara Y, et al. LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. Am J Ophthalmol 2007;144(4):608-612.
11. Sakurada Y, Kubota T, Mabuchi F, Imasawa M, et al. Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;145(6):1058-1062.
12. Gotoh N, Nakanishi H, Hayashi H, Yamada R, et al. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;147(6):1037-1041.
13. Lee KY, Vithana EN, Mathur R, Yong VH, et al. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 2008;49(6):2613-2619.
14. Kondo N, Honda S, Kuno S, Negi A. Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy. Ophthalmology 2009;116(2):304-310.
15. Ahuja RM, Stanga PE, Vingerling JR, Reck AC, et al. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. Br J Ophthalmol 2000;84(5):479-484.
16. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, et al. Indocyanine green videoangiography of idiopamic polypoidal choroidal vasculopathy. Retina 1995;15(2):100-110.
17. Lafaut BA, Leys AM, Snyers B, Rasquin F, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 2000;238(9):752-759.
18. Moorthy RS, Lyon AT, Rabb MF, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy of the macula. Ophthalmology 1998:105(8):1380-1385.
19. Okubo A, Sameshima M, Sakamoto T. Plasticity of polypoidal lesions in polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2004;242(11):962-965.
20. Sho K, Takahashi K, Yamada H, Wada M, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121(10):1392-1396.
21. Yamaoka S, Okada AA, Sugahara M, Hida T. Clinical features of polypoidal choroidal vasculopathy and visual outcomes in the absence of classic choroidal neovascularization. Ophthalmologica 2010;224(3):147-152.
22. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007;27(3):335-341.
23. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology 2003;110(1):15-21.
24. Okubo A, Ito M, Sameshima M, Uemura A, Sakamoto T. Pulsatile blood flow in the polypoidal choroidal vasculopathy. Ophthalmology 2005;112(8):1436-1441.
25. Sasahara M, Tsujikawa A, Musashi K, Gotoh N, et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 2006;142(4):601-607.
26. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol 2005;89(5):602-607.
27. Smith RE, Wise K, Kingsley RM. Idiopathic polypoidal choroidal vasculopathy and sickle cell retinopathy. Am J Ophthalmol 2000;129(4):544-546.
28. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000;107(4):767-777.
29. Tamura H, Tsujikawa A, Otani A, Gotoh N, et al. Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularization on fluorescein angiography. Br J Ophthalmol 2007; Vol. 91(9):1152-1159.
30. Bartlett HM, Willoughby B, Mandava N. Polypoidal choroidal vasculopathy in a patient with melanocytoma of the optic nerve. Retina 2001;21(4):396-399.
31. Li H, Wen F, Wu D. Polypoidal choroidal vasculopathy in a patient with circumscribed choroidal hemangioma. Retina 2004;24(4):629-631.
32. Mauget-Faysse M, Comut PL, Quaranta El-Maftouhi M, Leys A. Polypoidal choroidal vasculopathy in tilted disk syndrome and high myopia with staphyloma. Am J Ophthalmol 2006;142(6):970-975.
33. Iijima H, Iida T, Imai M, Gohdo T, Tsukahara S. Optical coherence tomography of orange-red subretinal lesions in eyes with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2000;129(1):21-26.
34. Ozawa S, Ishikawa K, Ito Y, Nishihara H, Yamakoshi T, et al. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography. Retina 2009;29(6):793-802.
35. Saito M, Iida T, Nagayama D. Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy. Retina 2008;28(3):459-464.
36. Sato T, Kishi S, Watanabe G, Matsumoto H, Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 2007;27(5):589-594.
37. Kwok AK, Lai TY, Chan CW, Neoh EL, et al. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002;86(8):892-897.
38. Maruko I, Iida T, Saito M, Nagayama D, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144(1):15-22.
39. Uyama M, Matsubara T, Fukushima I, Matsunaga H, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999;117(8):1035-1042.
40. Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol 2004;242(8):625-629.
41. Uyama M, Wada M, Nagai Y, Matsubara T, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133(5):639-648.
42. Chan WM, Lam DS, Lai TY, Liu DT, et al. Photodynamic therapy
43. with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004;111(8):1576-1584.
44. Leal S, Silva R, Figueira J, Cachulo ML, et al. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. Retina 2010;30(8):1197-1205.
45. Gomi F, Ohji M, Sayanagi K, Sawa M, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115(1):141-146.
46. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, et al. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 2012;96(3):394-399.
47. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92(1):70-73.
48. Lai TY, Chan WM, Liu DT, Luk FO, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92(5):661-666.
49. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010;94(3):297-301.
50. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 2007;14(9):1722-1727.
51. Okubo A, Ito M, Kamisasanuki T, Sakamoto T, et al. Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2005;243(8):837-839.
52. Lai TY, Lee GK, Luk FO, Lam DS. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011;31(8):1581-1588.
53. Lai TY, Lam CP, Luk FO, Chan RP, et al. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 2010;26(1):91-95.
54. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, et al. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;150(1):48-54.
55. Yuzawa M, Mori R, Haruyama M. A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003;47(4):379-384.
56. Nishijima K, Takahashi M, Akita J, Katsuta H, et al. Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2004;137(4):770-773.
57. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(1):39-44.
58. Lee WK, Lee PY, Lee SK. Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence. Jpn J Ophthalmol 2008;52(2):108-115.
59. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28(5):717-722.
60. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, et al. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008;92(7):936-940.
61. Kurashige Y, Otani A, Sasahara M, Yodoi Y, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146(4):513-519.
62. Mori R, Yuzawa M, Lee Z, Haruyama M, et al. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2010;248(9):1233-1239.
63. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, et al. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy. Retina 2011;31(5):857-865.
64. Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, et al. Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol 2011;151(6):961-972.
65. Nakata I, Yamashiro K, Yamada R, Gotoh N, et al. Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy. Ophthalmology 2011;118(7):1408-1415.
66. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, et al. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 2008;18(4):645-648.
67. Ghajarnia M, Kurup S, Eller A. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin Ophdialmol 2007;22(2):127-131.
68. Lee SY, Kim JG, Joe SG, Chung H, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008;22(2):92-99.
69. Song JH, Byeon SH, Lee SC, Koh HJ, et al. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009;223(2):85-92.
70. Cho M, Barbazetto IA, Freund KB. Refractory neovascular agerelated macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148(1):70-78.